US Medical Innovations (“USMI”) is a Maryland-based company that develops advanced plasma energy-based medical device products. USMI has 3 distinct platform technologies: USMI currently manufactures and sells the Canady Hybrid Plasma™ suite of FDA-approved electrosurgical and plasma-based surgical i…
US Medical Innovations (“USMI”) is a Maryland-based company that develops advanced plasma energy-based medical device products. USMI has 3 distinct platform technologies:
USMI currently manufactures and sells the Canady Hybrid Plasma™ suite of FDA-approved electrosurgical and plasma-based surgical instruments. This technology allows the surgeon to cut and coagulate biological tissue simultaneously – using one device. The benefits are less blood loss and transfusions, shorter hospital stays, and improved patient outcomes. These advantages have been clinically proven in an independent peer-reviewed study published in the Journal of Arthroplasty, the premier publication on joint replacement surgery. Since FDA approval, the Hybrid Plasma Scalpels have been used in over 20,000 surgeries.
USMI in the final phases of introducing the Canady Robotic™ Surgical System, a robotic-assisted, handheld laparoscopic surgical module. It will cost significantly less than the da Vinci robotic product line and will allow the surgeon to operate in a familiar setting – right next to the patient.
USMI’s development of its Helios Cold Plasma™ technology has the potential to be a paradigm shift in cancer treatment. It utilizes helium-based plasma to selectively kill cancerous cells. The FDA approved the use of USMI’s technology to treat a limited number of compassionate-use cases:
Helios Cold Plasma™ was used on a 75-year-old patient diagnosed with inoperable stage IV pancreatic cancer. Today, eight months after the groundbreaking surgery, the patient is alive and most importantly –cancer free. See the Fox News coverage of this surgery at http://www.fox32chicago.com/news/211496088-video.
The second patient is a 40-year-old woman with inoperable liver cancer. She underwent her first Helios Cold Plasma™ treatment in January 2017, and had her second treatment in March. So far, there is no evidence of recurrence.
The company is led by Dr. Jerome Canady, an experienced transplant surgeon with over 24 years of experience in the medical field and a leading figure in the clinical application of plasma in surgery.
Team (1)
Sectors US Medical Innovations serves:
Health Care
Join Axial's Private M&A Platform
US Medical Innovations connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
